RADIANCE: A Monocentric Prospective Randomized Study of Yttrium-90 Radioembolization With or Without Balloon Microcatheter in Patients With Unresectable Hepatocellular Carcinoma
Phase: Non-pharmacological interventional studies
Main Facility: Radiologia diagnostica ed Interventistica
Drug: Yttrium-90 (radioactive isotope used in microsphere-based therapy)
Pathologies: Hepatocellular carcinoma (HCC)
ClinicalTrials.gov: Read more about clinical trials
RADIANCE is a monocentric, prospective, randomized clinical study designed to evaluate the impact of using a balloon microcatheter during Yttrium-90 (Y-90) radioembolization in patients with unresectable hepatocellular carcinoma (HCC).
The study compares standard radioembolization versus balloon-assisted delivery, which may improve microsphere distribution, enhance tumor targeting, and reduce non-target embolization. The primary objectives typically include assessing treatment efficacy, tumor response, and safety, while secondary endpoints may include progression-free survival, overall survival, and procedural outcomes.
Last update: 20/04/2026